HC Wainwright Analysts Decrease Earnings Estimates for ABEO

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Abeona Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.36) per share for the quarter, down from their previous forecast of ($0.34). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.

A number of other brokerages also recently issued reports on ABEO. Oppenheimer initiated coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target on the stock. StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.50.

Abeona Therapeutics Trading Down 1.4 %

NASDAQ:ABEO traded down $0.07 during midday trading on Wednesday, hitting $4.97. The stock had a trading volume of 529,297 shares, compared to its average volume of 408,282. The company has a market capitalization of $241.21 million, a price-to-earnings ratio of -1.85 and a beta of 1.79. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average of $5.42 and a 200 day moving average of $5.81.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Twinbeech Capital LP acquired a new stake in Abeona Therapeutics in the 4th quarter worth approximately $58,000. Squarepoint Ops LLC acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at $67,000. Jane Street Group LLC purchased a new position in Abeona Therapeutics in the 3rd quarter worth $84,000. Oxford Asset Management LLP acquired a new stake in Abeona Therapeutics during the 4th quarter worth about $118,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Abeona Therapeutics during the 3rd quarter valued at about $151,000. Institutional investors and hedge funds own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.